Carrot Medical Closes a Strong 1st Quarter

Carrot Medical is pleased to report strong preliminary numbers for Q1, 2017. Top and bottom line steadily improved. Comparing Q1, 2017 to Q1, 2016 – Revenue grew by 31%, OPEX increased by 6% and EBITDA rose by 134%. Carrot continues to exceed the expectations of its customers and orders are increasing both for new products as well as new services. “We continue to see double digit growth quarter over quarter from 2015 to now Q1 of 2017,” said Jeremy Wiggins, Carrot Medical CEO. “2015 was a record year in terms of being EBITDA positive. In 2016 – we achieved that goal along with Net Profit. For 2017 – we’ll set the bar even higher for EBITDA, Net Profit and record Revenue. Our expanding customer base, new Platform Releases, and Professional Services have us all extremely motivated for another banner year at Carrot Medical.”